We read with interest the retrospective study by Loft et al., which leveraged data from the ACCORD database [1].The authors analyzed 459 patients with Stage III colon cancer undergoing adjuvant chemotherapy to examine whether concomitant use of proton pump inhibitors (PPIs) influences survival outcomes.This is a clinically relevant question: 31% of patients were taking PPIs during chemotherapy, so a confirmed drug interaction would carry substantial implications for prescribing.However, we are concerned that the study's principal positive finding lacks statistical robustness for the following reasons.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: